Company: CRVO
Filing Date: 2025-05-12
Form Type: 424B5
Source: 0001437749-25-016167
Chunk: 16

Company: CervoMed Inc.
Filing Date: 2025-05-12
Form: 424B5
Chunk 16
---
 investment-grade instruments, certificates of deposit, direct or guaranteed obligations of the U.S. government, or similar cash equivalents and marketable securities.

<div align='center'>S-10

DIVIDEND POLICY</div>

We have not paid any cash dividends on our common stock to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition. The payment of any cash dividends will be within the discretion of the board of directors at such time.

<div align='center'>S-11

DILUTION</div>

If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the public offering price per share in this offering and the as adjusted net tangible book value per share immediately after this offering.

As of March 31, 2025, our historical net tangible book value was approximately $34.6 million, or $3.98per share. Historical net tangible book value per share is equal to the amount of our total tangible assets less our total liabilities, divided by 8,702,719, the number of shares of common stock outstanding as of March 31, 2025.

After giving effect to the assumed sale of our common stock in the aggregate offering amount of approximately $50,000,000at an assumed offering price of $8.49 per share, the last reported sale price of our common stock on The NASDAQ Capital Market on May 9, 2025, and after deducting commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of March 31, 2025 would have been approximately $82.2 million, or $5.63 per share. This amount represents an immediate increase in net tangible book value of $1.65per share to our existing stockholders and an immediate dilution in net tangible book value of approximately $2.86 per share to new investors in this offering.

The following table illustrates this calculation on a per share basis. The as adjusted information is illustrative only and will adjust based on the actual price to the public, the actual number of shares sold and other terms of the offering determined at the time shares of our common stock are sold pursuant to this prospectus supplement. The shares sold in this offering, if any, will be sold from time to time at various prices.

| Assumed public offering price per share                                                   |     |   |      |     | $ | 8.